In a groundbreaking development that could transform the landscape of Alzheimer’s disease treatment, scientists have identified a natural molecule that appears capable of reversing memory loss associated with this devastating condition. Published in the journal Science Advances, new research reveals that NAD+ (nicotinamide adenine dinucleotide) works through a previously unknown mechanism involving the EVA1C protein to correct errors in RNA splicing, a process gone awry in Alzheimer’s disease.
A Global Health Crisis in Need of New Solutions
With approximately 55 million people worldwide currently living with dementia—of which Alzheimer’s disease accounts for 60-80%—the need for effective treatments has never been more urgent. According to the World Health Organization, this number is projected to triple by 2050 as global populations age. The economic burden is equally staggering, with dementia costing the global economy an estimated $1.3 trillion annually, a figure expected to rise to $2 trillion by 2030.
Alzheimer’s disease is characterized by the accumulation of abnormal proteins in the brain, particularly tau tangles and amyloid plaques, which disrupt cellular function and lead to progressive cognitive decline. Current treatments can only temporarily alleviate symptoms without addressing the underlying disease progression, leaving patients and families desperately seeking more effective solutions.
The NAD+ Breakthrough: How It Works
The research, conducted by an international collaboration including the University of Oslo, Norway’s Akershus University Hospital, China’s Jinan University, and the University of Minho in Portugal, uncovered a novel therapeutic pathway for Alzheimer’s disease. Previously, NAD+ was primarily understood for its role in cellular energy metabolism, but this study reveals a more profound mechanism linked to the fundamental process of RNA splicing.
Understanding RNA Splicing Errors
RNA splicing is a crucial cellular process that allows a single gene to produce multiple protein variants, enabling cellular diversity and function. In Alzheimer’s disease, this essential mechanism becomes dysregulated, leading to what researchers term “editing errors” that produce dysfunctional proteins and accelerate neuronal death. As explained by the study’s lead author Alice Ruixue Ai from UiO and Ahus, “In AD, RNA splicing – which tells cells how to assemble proteins – goes awry, producing dysfunctional proteins that accelerate the irreversible death of neurons.”
The NAD+-EVA1C Pathway
The researchers discovered that NAD+ can correct these splicing errors through its interaction with EVA1C (epithelial V-like antigen 1 homolog C), a protein that manages how RNA messages are assembled. Their experiments began with genetically modified worms (Caenorhabditis elegans) engineered to produce toxic human tau protein, providing a simple model to test whether boosting NAD+ could fix RNA splicing errors. The results were promising: increased NAD+ levels corrected age- and tau-related splicing issues and improved movement and learning behaviors in the worms.
In mouse models carrying mutant tau, the researchers found that hundreds of genes involved in RNA processing were misregulated, particularly those related to splicing. When they boosted NAD+ levels using precursors such as nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN), these errors were corrected. Further testing revealed that silencing EVA1C eliminated NAD+’s protective effects, confirming its essential role in this therapeutic mechanism.
The validation came from human brain samples of Alzheimer’s patients, where scientists found significantly reduced EVA1C protein levels in the hippocampus and entorhinal cortex—regions critical for memory and early disease progression. As associate professor Evandro Fei Fang-Stavem from UiO noted, “Notably, we found when the EVA1C gene was knocked down, these benefits were lost, confirming that EVA1C is essential for NAD+-mediated neuroprotection.”
Clinical Applications and Regulatory Status
This discovery has significant implications for developing new treatments, particularly through NAD+ precursors like NR and NMN, which are already available as dietary supplements. Early clinical trials have shown cognitive improvements in patients with mild cognitive impairment, though larger studies are needed to confirm efficacy in Alzheimer’s disease specifically. However, the regulatory landscape remains complex, with the FDA not yet approving these compounds for Alzheimer’s treatment. According to the U.S. Food and Drug Administration, while NR and NMN are marketed as supplements, they lack formal approval for treating neurodegenerative diseases.
Current clinical research, as documented in databases like ClinicalTrials.gov, includes various studies evaluating NAD+ precursors for cognitive protection, with several ongoing trials investigating their effects on biomarkers and cognitive measures in aging populations. The evidence, while promising, remains preliminary, with most definitive results still pending.
The Broader Implications for Aging and Neurodegeneration
NAD+ is not just a player in Alzheimer’s disease—it’s a fundamental molecule in cellular health that naturally declines with age. Beyond its newfound role in RNA splicing correction, NAD+ is crucial for energy metabolism, DNA repair, and maintaining cellular function. The growing focus on this molecule in geroscience—the study of aging’s biological mechanisms—reflects a paradigm shift toward addressing age-related diseases at their metabolic roots.
This research positions the NAD+-EVA1C pathway as a potential therapeutic target that could not only preserve memory but also slow the broader neurodegenerative process. As Ai suggests, “We propose that maintaining NAD+ levels could help preserve neuronal identity and delay cognitive decline, paving the way for combination treatments to enhance RNA splicing.”
Looking Forward
While we’re not yet at the point of clinical application, this discovery represents a significant shift in understanding how to approach Alzheimer’s disease treatment. Rather than simply targeting amyloid plaques or tau tangles, scientists now have a new strategy that addresses fundamental cellular dysfunction. The combination of naturally occurring molecules like NAD+ with the precision of targeting specific protein pathways offers hope for more effective interventions.
For families affected by Alzheimer’s disease, this research offers something perhaps more valuable than immediate treatment: hope and validation that the scientific community is making meaningful progress against this devastating condition. As one New Atlas reader commented, “Come on, Science. I really hope you figure this out soon. Literally the one and only thing in this life that I fear is going out like my grandad did.”
The path from laboratory discovery to approved treatment remains long and uncertain, but this research provides a compelling roadmap for future investigations. With continued study and clinical validation, NAD+ supplementation might one day become part of a comprehensive approach to maintaining cognitive health throughout aging—a prospect that would represent tremendous progress in our fight against Alzheimer’s disease.
Leave a Reply